Lupeng Pharmaceutical

About Lupeng Pharmaceutical

Lupeng Pharmaceutical, established in Guangzhou, China, in June 2018 by co-founders Dr. Fenlai Tan and Dr. Yi Chen, is a clinical-stage biopharmaceutical company focused on creating small-molecule drugs for cancers and autoimmune diseases. The firm operates with a clear objective to design and develop therapeutics that address significant unmet medical needs, particularly targeting pathways like BTK, Bcl-2, and Bcl-xL in hematological tumors. Dr. Tan, who serves as Chairman and CEO, brings extensive experience in clinical trial design and commercialization, having previously co-founded Betagen Pharma and led the development of several new drugs. Dr. Chen's expertise lies in novel drug design and preclinical development.

The company's business model is centered on the in-house research, development, and eventual commercialization of its drug pipeline. Lupeng Pharmaceutical generates revenue through strategic partnerships and licensing agreements. A notable example is the collaboration with Hansoh Pharma for the development and commercialization of LP-168 in non-tumor indications within China, a deal valued at up to RMB729 million in milestone payments plus royalties. The company has successfully raised over $110 million from prominent investors, including Temasek, Kaitai Capital, Lilly Asia Ventures, and Lake Bleu Capital, to fund its clinical trials and pipeline expansion. These funds are directed towards advancing its portfolio of more than 10 drug candidates.

Lupeng's product pipeline features several promising candidates in various stages of clinical development across China, the United States, and Europe. The core programs include Rocbrutinib (LP-168), a next-generation BTK inhibitor, and Lacutoclax (LP-108), a selective Bcl-2 inhibitor. Rocbrutinib's New Drug Application was accepted by China's CDE for treating relapsed or refractory mantle cell lymphoma. Lacutoclax has also received approval to enter pivotal registration trials. The company's strategy involves focusing on targets with high unmet needs, challenging medicinal chemistry, and strong synergy with its core programs, aiming to build a fully integrated biopharmaceutical company with R&D, manufacturing, and commercialization capabilities.